SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending significantly ahead of its earnings call, with market participants heavily debating its aggressive AI data center investments, the associated debt, and the status of key cloud partnerships. The community is focused on whether its substantial cloud growth and AI backlog can offset concerns about capital expenditures, positioning this event as a critical read for the broader AI infrastructure sector.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after reporting its first-ever quarterly profit and strong delivery guidance, fueling community excitement over a potential short squeeze and comparisons to past EV growth rallies, despite facing immediate price resistance.

CitroTech, Inc. is an integrated environmental service company, which engages in the provision of field services, remediation transportation, and EHS compliance services. It also offers on-site technical services, on-site and off-site treatment for hazardous and non-hazardous waste. The company was founded on March 14, 1990 and is headquartered in Cheyenne, WY.

CitroTech Inc.

CitroTech Inc. (CITR) is generating strong trading momentum and community buzz due to its presentation at the iAccess Alpha conference, showcasing its differentiated fire-retardant wood technology, with its low share float driving speculation of a significant re-rating if commercial traction continues.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following impressive Q4 financial results, which showcased strong revenue growth from its rare disease drug MIPLYFFA and a significant shift to profitability, sparking community discussions about its re-valuation as a commercial-stage enterprise. Anticipation for European approval of MIPLYFFA, coupled with increased analyst price targets and high trading volume, is fueling speculation among investors.

Hydrograph Clean Power, Inc. engages in the research, development, marketing and commercialization of patented technology to produce pristine graphene, graphene derivatives and services. The company was founded by Harold Charles Davidson on June 26, 2017 and is headquartered in Vancouver, Canada.

Hydrograph Clean Power Inc

HGRAF is surging amid regulatory clearances for its ultra-pure graphene in key markets and anticipation of its Austin facility launch and NASDAQ uplisting, with the community actively debating its potential to revolutionize industries and secure major commercial contracts.

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

Polaryx Therapeutics Inc.

Polaryx Therapeutics (PLYX), a clinical-stage biotech focusing on rare diseases, is highly volatile following its announcement of a CRO selection for its PLX-200 Phase 2 trial, sparking intense community speculation around short squeeze potential given its low float and direct listing structure.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is making new all-time highs and fueling bullish community sentiment following its transformative acquisition of Covelya Group, integrating key subsea technologies to become a dominant player in underwater defense and marine infrastructure. Investors are actively discussing its strategic expansion, crucial partnerships, and potential future NASDAQ uplisting.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending due to widespread community frustration and confusion surrounding its announced proposed convertible senior notes offering, with many questioning management's strategic intentions for raising capital despite existing substantial cash reserves and speculating on possible institutional arbitrage plays.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund (USO) is experiencing extreme volatility driven by presidential remarks suggesting the Middle East conflict is "very complete" and conflicting reports regarding US Navy escorts through the Strait of Hormuz. The community is intensely debating whether these signals indicate genuine de-escalation or market manipulation, as concerns persist over shipping security and potential strategic oil reserve releases.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending amidst heightened geopolitical anxiety following reports of Iran preparing to deploy naval mines in the Strait of Hormuz, which immediately impacts oil prices and global shipping. This development is intensifying market volatility and community debate, especially given the administration's conflicting messages on the conflict's status.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down - What's Next?

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down - Time to Sell...

After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Oric Pharmaceuticals, Inc. $ORIC Stake Raised by Royce & Associates LP

Royce & Associates LP raised its holdings in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 521.2% in the third quarter, according to its most recent 13F filing with the Securities and...

Oric Pharmaceuticals Teases Key 2026 Catalysts, Phase 3 Plans for Prostate and Lung Cancer Drugs

Executives from Oric Pharmaceuticals (NASDAQ:ORIC) used a conference discussion to highlight near-term clinical catalysts for its two lead oncology programs and to outline how upcoming data could...

Oric Pharmaceuticals (NASDAQ:ORIC) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Oric Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday...

Oric Pharmaceuticals (NASDAQ:ORIC) CFO Sells $702,520.00 in Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 52,000 shares of the firm's stock in a transaction on Tuesday, February 24th. The shares were sold at an average...

Dominic Piscitelli Sells 52,000 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 52,000 shares of Oric Pharmaceuticals stock in a transaction that occurred on Tuesday, February 24th. The shares...

Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to Trade

The mean of analysts' price targets for Oric Pharmaceuticals (ORIC) points to a 58.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Q1 EPS Forecast for Oric Pharmaceuticals Raised by Analyst

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - HC Wainwright lifted their Q1 2026 earnings estimates for Oric Pharmaceuticals in a research note issued to investors on Tuesday, February...

Oric Pharmaceuticals (NASDAQ:ORIC) Trading 7.9% Higher Following Earnings Beat

Oric Pharmaceuticals (NASDAQ:ORIC) Trading 7.9% Higher on Strong Earnings...

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $ORCL earnings Tuesday?

Current Price	$12.39
Prev Close	$11.65
Open	$12.17
Dividend Yield	0.00%
50-Day Moving Average	$10.88
Beta	1.63
Avg. Volume	1.52M
PE Ratio	-7.69

52-Week High	$14.93
52-Week Low	$3.90
Market Capitalization	$1.17B
EPS (Annual)	-$1.47
Price to Book	2.99
Revenue Per Employee	$0.00

ORIC
ORIC Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ORIC News

ORICORIC Pharmaceuticals Inc